Skip to main content

Table 6 Incidence (mean) of acute anterior uveitis (AAU) and inflammatory bowel disease (IBD) and respective 95% CIs calculated using a normal approximation. Data from different studies were pooled when the same outcomes from the same treatments were available and when they referred to doses and/or regimens approved in Brazil. * 95% CI reported by the authors of the original study. ** No new case or reactivation was reported in the study with golimumab IV. The incidence of this event was not described in studies with SC golimumab injections

From: The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis – 2019

Outcome Incidence (events/100 PY)
Drug AAU Incidence 95% CI IBD Incidence 95% CI
Infliximab [179, 189] 3.4 0.5–6.4 0.2 0–0.9*
Etanercept [179, 189] 7.9 5.4–10.5 1.3 0–4.2*
Adalimumab [180, 189] 7.4 4.7–10.1 0.8 0.6–2.5*
Golimumab [133, 138, 187] 2.2 0–5.2 0**
Certolizumab pegol [141, 186] 4.9 3.0–6.9 0.1 0–0.3
Secukinumab [142] 1.0 0.3–1.8 0.7 0.1–1.3